Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants
Accelerated Approval Adds Another Alzheimer’s Study To Global Pipeline
Executive Summary
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.